Candy giant Hershey is getting a sales boost from an unexpected consumer segment: users of GLP-1 weight-loss drugs. Hershey CEO Kirk Tanner said  in the company's first-quarter earnings call on Thursday that while appetite suppressants are leading customers to consume smaller portions of popular snacks, the drugs are also boosting demand for breath fresheners.  The company has "seen strong demand for gum and mint products as the category benefits from functional snacking tailwinds, including